Anti-inflammatory drug development: Broad or specific chemokine receptor antagonists?

Current Opinion in Drug Discovery and Development

Volumn 13, Issue 4, 2010, Pages 414-427

  Russo, Remo Castro ^a   Garcia, Cristiana Couto ^a   Teixeira, Mauro Martins ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Antagonist; autoimmune disease; chemokine; chemokine receptor; chronic inflammatory disease; immune evasion; inflammation; leukocyte

Indexed keywords

ANTIINFLAMMATORY AGENT; CCX 282; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL16 CHEMOKINE; EOTAXIN; FRACTALKINE; GRANULOCYTE COLONY STIMULATING FACTOR; MARAVIROC; MLN 3897; MONOCYTE CHEMOTACTIC PROTEIN 2; PLERIXAFOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; BINDING AFFINITY; CLINICAL TRIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INFECTION; INFLAMMATORY DISEASE; LEUKOCYTE ACTIVATION; LEUKOCYTE MIGRATION; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; NONHUMAN; PHYSIOLOGY; PUBLICATION; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; INFLAMMATION; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DRUG DISCOVERY; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION;

EID: 77954650443     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Murphy PM: The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol (1994) 12: 593-633.
2. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA: International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev (2000)52(1):145-176.
3. Luster AD: Chemokines - Chemotactic cytokines that mediate inflammation. N Engl J Med (1998)338(7):436-445.
4. Rot A: Neutrophil attractant/activation protein-1 (interleukin-8) induces in vitro neutrophil migration by haptotactic mechanism. Eur J Immunol (1993)23(1):303-306.
5. Michel G, Kemeny L, Peter RU, Beetz A, Ried C, Arenberger P, Ruzicka T: Interleukin-8 receptor-mediated chemotaxis of normal human epidermal cells. FEBS Lett (1992)305(3):241-243.
6. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM: Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science (1992)258(5089):1798-1801.
7. Ishida Y, Kimura A, Kondo T, Hayashi T, Ueno M, Takakura N, Matsushima K, Mukaida N: Essential roles of the CC chemokine ligand 3-CC chemokine receptor 5 axis in bleomycin-induced pulmonary fibrosis through regulation of macrophage and fibrocyte infiltration. Am J Pathol (2007)170(3):843-854.
8. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR: Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature (1998)393(6685):595-599.
9. Vandercappellen J, Van Damme J, Struyf S: The role of CXC chemokines and their receptors in cancer. Cancer Lett (2008)267(2):226-244.
10. Lumeng CN, Bodzin JL, Saltiel AR: Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest (2007)117(1):175-184.
11. Dorner BG, Dorner MB, Zhou X, Opitz C, Mora A, Guttler S, Hutloff A, Mages HW, Ranke K, Schaefer M, Jack RS et al: Selective expression of the chemokine receptor XCR1 on crosspresenting dendritic cells determines cooperation with CD8+ T cells. Immunity (2009)31(5):823-833.
12. Lim JK, Glass WG, McDermott DH, Murphy PM: CCR5: No longer a 'good for nothing' gene - Chemokine control of West Nile Virus infection. Trends Immunol (2006)27(7):308-312.
13. Wang E, Worschech A, Marincola FM: The immunologic constant of rejection. Trends Immunol (2008)29(6):256-262.
14. Walz DA, Wu VY, de Lamo R, Dene H, McCoy LE: Primary structure of human platelet factor 4. Thromb Res (1977)11(6):893-898.
15. Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, Leonard EJ: Purification of a human monocytederived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA (1987)84(24):9233-9237.
16. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, Buser R, Wells TN, Proudfoot AE: Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science (1997)276(5310):276-279.
17. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science (1995)270(5243):1811- 1815. • Describes the blockade of HIV infection by chemokines.
18. Locati M, Otero K, Schioppa T, Signorelli P, Perrier P, Baviera S, Sozzani S, Mantovani A: The chemokine system: Tuning and shaping by regulation of receptor expression and coupling in polarized responses. Allergy (2002)57(11):972-982.
19. Proudfoot AE: Chemokine receptors: Multifaceted therapeutic targets. Nat Rev Immunol (2002)2(2):106-115.
20. Mantovani A: The chemokine system: Redundancy for robust outputs. Immunol Today (1999)20(6):254-257.
21. Salanga CL, O'Hayre M, Handel T: Modulation of chemokine receptor activity through dimerization and crosstalk. Cell Mol Life Sci (2009)66(8):1370-1386. •• A review focusing on chemokine receptor dimerization that discusses the relevance of dimerization for chemokine receptor signaling.
22. Thelen M, Munoz LM, Rodriguez-Frade JM, Mellado M: Chemokine receptor oligomerization: Functional considerations. Curr Opin Pharmacol (2010)10(1):38-43.
23. Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, Borlat F, Wells TN, Kosco-Vilbois MH: Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA (2003)100(4):1885-1890.
24. Allen SJ, Crown SE, Handel TM: Chemokine: Receptor structure, interactions, and antagonism. Annu Rev Immunol (2007) 25: 787-820.
25. Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L, Sozzani S, Mantovani A, Altruda F, Wymann MP: Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation. Science (2000)287(5455): 1049-1053.
26. Scandella E, Men Y, Legler DF, Gillessen S, Prikler L, Ludewig B, Groettrup M: CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood (2004)103(5):1595-1601.
27. Ramos CD, Canetti C, Souto JT, Silva JS, Hogaboam CM, Ferreira SH, Cunha FQ: MIP-1α[CCL3] acting on the CCR1 receptor mediates neutrophil migration in immune inflammation via sequential release of TNF-α and LTB4. J Leukoc Biol (2005)78(1):167-177.
28. 4. Eur J Immunol (2006)36(8):2025-2034.
29. Sozzani S, Rieppi M, Locati M, Zhou D, Bussolino F, Proost P, Van Damme J, Mantovani A: Synergism between platelet activating factor and C-C chemokines for arachidonate release in human monocytes. Biochem Biophys Res Commun (1994)199(2):761-766.
30. 2+ influx, synergism with platelet-activating factor and significance for chemotaxis. J Biol Chem (1994)269(7):4746-4753.
31. Klein A, Talvani A, Silva PM, Martins MA, Wells TN, Proudfoot A, Luckacs NW, Teixeira MM: Stem cell factor-induced leukotriene B4 production cooperates with eotaxin to mediate the recruitment of eosinophils during allergic pleurisy in mice. J Immunol (2001)167(1):524-531.
32. Viola A, Luster AD: Chemokines and their receptors: Drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol (2008) 48: 171-197.
33. Thelen M, Stein JV: How chemokines invite leukocytes to dance. Nat Immunol (2008)9(9):953-959.
34. Patel M, McInnes IB, Graham G: Atypical chemokine receptors in inflammatory disease. Curr Mol Med (2009)9(1):86-93.
35. Graham GJ: D6 and the atypical chemokine receptor family: Novel regulators of immune and inflammatory processes. Eur J Immunol (2009)39(2):342-351.
36. Mantovani A, Bonecchi R, Locati M: Tuning inflammation and immunity by chemokine sequestration: Decoys and more. Nat Rev Immunol (2006)6(12):907-918.
37. Naumann U, Cameroni E, Pruenster M, Mahabaleshwar H, Raz E, Zerwes HG, Rot A, Thelen M: CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS One (2010)5(2):e9175.
38. Zlotnik A, Yoshie O, Nomiyama H: The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol (2006)7(12):243.
39. Fallon PG, Alcami A: Pathogen-derived immunomodulatory molecules: Future immunotherapeutics? Trends Immunol (2006)27(10):470-476. • Provides an overview of immunomodulatory molecules, including chemokine-binding proteins produced by diverse pathogens that may be used by the pathogen to escape immune surveillance.
40. Liston A, McColl S: Subversion of the chemokine world by microbial pathogens. Bioessays (2003)25(5):478-488.
41. Frauenschuh A, Power CA, Deruaz M, Ferreira BR, Silva JS, Teixeira MM, Dias JM, Martin T, Wells TN, Proudfoot AE: Molecular cloning and characterization of a highly selective chemokine-binding protein from the tick Rhipicephalus sanguineus. J Biol Chem (2007)282(37):27250-27258.
42. Rosenkilde MM: Virus-encoded chemokine receptors - Putative novel antiviral drug targets. Neuropharmacology (2005)48(1):1-13.
43. Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, Anderson M, Schroder JM, Wang JM, Howard OM, Oppenheim JJ: β-Defensins: Linking innate and adaptive immunity through dendritic and T cell CCR6. Science (1999)286(5439):525-528. • Describes the interaction and activity of β-defensins and CCR6.
44. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, Kooistra T et al: MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med (2007)13(5):587-596.
45. Floto RA, MacAry PA, Boname JM, Mien TS, Kampmann B, Hair JR, Huey OS, Houben EN, Pieters J, Day C, Oehlmann W et al: Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5. Science (2006)314(5798):454-458.
46. Weathington NM, van Houwelingen AH, Noerager BD, Jackson PL, Kraneveld AD, Galin FS, Folkerts G, Nijkamp FP, Blalock JE: A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med (2006)12(3):317-323.
47. Degryse B, de Virgilio M: The nuclear protein HMGB1, a new kind of chemokine? FEBS Lett (2003)553(1-2):11-17.
48. Mortier A, Van Damme J, Proost P: Regulation of chemokine activity by posttranslational modification. Pharmacol Ther (2008)120(2):197-217. •• Provides a good review of post-translational chemokine-processing mechanisms by endogenous enzymes.
49. Ludwig A, Weber C: Transmembrane chemokines: Versatile 'special agents' in vascular inflammation. Thromb Haemost (2007)97(5):694-703.
50. Petkovic V, Moghini C, Paoletti S, Uguccioni M, Gerber B: I-TAC/CXCL11 is a natural antagonist for CCR5. J Leukoc Biol (2004)76(3):701-708.
51. Johnson Z, Schwarz M, Power CA, Wells TN, Proudfoot AE: Multi-faceted strategies to combat disease by interference with the chemokine system. Trends Immunol (2005)26(5):268-274.
52. Proudfoot AE, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, Offord RE, Wells TN: Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem (1996)271(5):2599-2603.
53. Allegretti M, Bertini R, Bizzarri C, Beccari A, Mantovani A, Locati M: Allosteric inhibitors of chemoattractant receptors: Opportunities and pitfalls. Trends Pharmacol Sci (2008)29(6):280-286.
54. Ruckle T, Schwarz MK, Rommel C: PI3Kγ inhibition: Towards an 'aspirin of the 21st century'? Nat Rev Drug Discov (2006)5(11):903-918. •• An outstanding review focusing on targeting PI3Kγ to reduce inflammation - an interesting approach to interfering with downstream signaling by the chemokine system.
55. Firestein GS: Evolving concepts of rheumatoid arthritis. Nature (2003)423(6937):356-361.
56. Ruth JH, Rottman JB, Katschke KJ Jr, Qin S, Wu L, LaRosa G, Ponath P, Pope RM, Koch AE: Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum (2001)44(12):2750-2760.
57. Haringman JJ, Smeets TJ, Reinders-Blankert P, Tak PP: Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann Rheum Dis (2006)65(3):294-300.
58. Ribeiro S, Horuk R: The clinical potential of chemokine receptor antagonists. Pharmacol Ther (2005)107(1):44-58.
59. Katschke KJ Jr, Rottman JB, Ruth JH, Qin S, Wu L, LaRosa G, Ponath P, Park CC, Pope RM, Koch AE: Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum (2001)44(5):1022-1032.
60. Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, Pope RM, Strieter RM: Macrophage inflammatory protein-1 α. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest (1994)93(3):921-928.
61. Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I: An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med (1997)186(1):131-137.
62. Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, van den Bosch F, Bresnihan B, Breedveld FC, Dinant HJ, Legay F, Gram H, Loetscher P et al: A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum (2006)54(8):2387-2392.
63. Vergunst CE, Gerlag DM, Lopatinskaya L, Klareskog L, Smith MD, van den Bosch F, Dinant HJ, Lee Y, Wyant T, Jacobson EW, Baeten D et al: Modulation of CCR2 in rheumatoid arthritis: A double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum (2008)58(7):1931-1939.
64. Revesz L, Bollbuck B, Buhl T, Eder J, Esser R, Feifel R, Heng R, Hiestand P, Jachez-Demange B, Loetscher P, Sparrer H et al: Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis. Bioorg Med Chem Lett (2005)15(23):5160-5164.
65. Amat M, Benjamim CF, Williams LM, Prats N, Terricabras E, Beleta J, Kunkel SL, Godessart N: Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo. Br J Pharmacol (2006)149(6):666-675.
66. Haringman JJ, Kraan MC, Smeets TJ, Zwinderman KH, Tak PP: Chemokine blockade and chronic inflammatory disease: Proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis (2003)62(8):715-721.
67. Vergunst CE, Gerlag DM, von Moltke L, Karol M, Wyant T, Chi X, Matzkin E, Leach T, Tak PP: MLN3897 plus methotrexate in patients with rheumatoid arthritis: Safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study. Arthritis Rheum (2009)60(12):3572-3581.
68. Barnes DA, Tse J, Kaufhold M, Owen M, Hesselgesser J, Strieter R, Horuk R, Perez HD: Polyclonal antibody directed against human RANTES ameliorates disease in the lewis rat adjuvant-induced arthritis model. J Clin Invest (1998)101(12):2910-2919.
69. Quinones MP, Ahuja SK, Jimenez F, Schaefer J, Garavito E, Rao A, Chenaux G, Reddick RL, Kuziel WA, Ahuja SS: Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J Clin Invest (2004)113(6):856-866.
70. Plater-Zyberk C, Hoogewerf AJ, Proudfoot AE, Power CA, Wells TN: Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett (1997)57(1-3):117-120.
71. Vierboom M P, Zavodny PJ, Chou CC, Tagat JR, Pugliese-Sivo C, Strizki J, Steensma R W, McCombie SW, Celebi-Paul L, Remarque E, Jonker M et al: Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. Arthritis Rheum (2005)52(2):627-636.
72. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G et al: Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996)382(6593):722-725.
73. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996)86(3):367-377.
74. Martens HA, Kallenberg CG, Bijl M: Role of CCR5 δ32 bp deletion in RA and SLE. Autoimmunity (2009)42(4):260-262.
75. Rottman JB, Slavin AJ, Silva R, Weiner HL, Gerard CG, Hancock WW: Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur J Immunol (2000)30(8):2372-2377.
76. Zipp F, Hartung HP, Hillert J, Schimrigk S, Trebst C, Stangel M, Infante-Duarte C, Jakobs P, Wolf C, Sandbrink R, Pohl C et al: Blockade of chemokine signaling in patients with multiple sclerosis. Neurology (2006)67(10):1880-1883.
77. Reuss R, Schreiber V, Klein A, Infante-Duarte C, Filippi M, Pabst W, Pohl C, Oschmann P: No significant effect of orally administered chemokine receptor 1 antagonist on intercellular adhesion molecule-3 expression in relapsing - Remitting multiple sclerosis patients. Mult Scler (2010)16(3):366-369.
78. Handel TM, Johnson Z, Rodrigues DH, Dos Santos AC, Cirillo R, Muzio V, Riva S, Mack M, Deruaz M, Borlat F, Vitte PA et al: An engineered monomer of CCL2 has anti-inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo. J Leukoc Biol (2008)84(4):1101-1108.
79. dos Santos AC, Barsante MM, Arantes RM, Bernard CC, Teixeira MM, Carvalho-Tavares J: CCL2 and CCL5 mediate leukocyte adhesion in experimental autoimmune encephalomyelitis - An intravital microscopy study. J Neuroimmunol (2005)162(1-2):122-129.
80. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD: Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR) 2. J Exp Med (2000)192(7):1075-1080.
81. Proudfoot AE, Power CA, Schwarz MK: Anti-chemokine small molecule drugs: A promising future? Expert Opin Investig Drugs (2010)19(3):345-355.
82. Kohler RE, Comerford I, Townley S, Haylock-Jacobs S, Clark-Lewis I, McColl SR: Antagonism of the chemokine receptors CXCR3 and CXCR4 reduces the pathology of experimental autoimmune encephalomyelitis. Brain Pathol (2008)18(4):504-516.
83. Hunt JS, Romanelli F: Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1. Pharmacotherapy (2009)29(3):295-304.
84. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB et al: Maraviroc for previously treated patients with r5 HIV-1 infection. N Engl J Med (2008)359(14):1429-1441. • Reports the phase III clinical trial of maraviroc, a CCR5 antagonist, in patients with HIV.
85. Sayana S, Khanlou H: Maraviroc: A new CCR5 antagonist. Expert Rev Anti Infect Ther (2009)7(1):9-19.
86. Kessans MR, Gatesman ML, Kockler DR: Plerixafor: A peripheral blood stem cell mobilizer. Pharmacotherapy (2010)30(5):485-492.
87. Nishimura M, Kuboi Y, Muramoto K, Kawano T, Imai T: Chemokines as novel therapeutic targets for inflammatory bowel disease. Ann NY Acad Sci (2009) 1173 (350-356. • Describes effective and ineffective chemokine targets, such as CCR9, that have been investigated in animal models of IBD and in clinical trials.
88. Papadakis KA, Prehn J, Moreno ST, Cheng L, Kouroumalis EA, Deem R, Breaverman T, Ponath PD, Andrew DP, Green PH, Hodge MR et al: CCR9-positive lymphocytes and thymusexpressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology (2001)121(2):246-254.
89. Rivera-Nieves J, Ho J, Bamias G, Ivashkina N, Ley K, Oppermann M, Cominelli F: Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology (2006)131(5):1518-1529.
90. Product pipeline - Our PROTECT-1 clinical trial in Crohn's disease: ChemoCentryx Inc, Mountain View, CA, USA (2010). www.chemocentryx.com/contact/ contact.html
91. Proudfoot AE, de Souza AL, Muzio V: The use of chemokine antagonists in EAE models. J Neuroimmunol (2008)198(1-2):27-30.
92. Saita Y, Kondo M, Shimizu Y: Species selectivity of smallmolecular antagonists for the CCR5 chemokine receptor. Int Immunopharmacol (2007)7(12):1528-1534.
93. Nagase H, Yamaguchi M, Jibiki S, Yamada H, Ohta K, Kawasaki H, Yoshie O, Yamamoto K, Morita Y, Hirai K: Eosinophil chemotaxis by chemokines: A study by a simple photometric assay. Allergy (1999)54(9):944-950.
94. Teixeira MM, Wells TN, Lukacs NW, Proudfoot AE, Kunkel SL, Williams TJ, Hellewell PG: Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin. J Clin Invest (1997)100(7):1657-1666.
95. Lim JK, McDermott DH, Lisco A, Foster GA, Krysztof D, Follmann D, Stramer SL, Murphy PM: CCR5 deficiency is a risk factor for early clinical manifestations of West Nile Virus infection but not for viral transmission. J Infect Dis (2010)201(2):178-185.
96. Falcao PL, Correa-Oliveira R, Fraga LA, Talvani A, Proudfoot AE, Wells TN, Williams TJ, Jose PJ, Teixeira MM: Plasma concentrations and role of macrophage inflammatory protein-1α during chronic Schistosoma mansoni infection in humans. J Infect Dis (2002)186(11):1696-1700.
97. Souza AL, Roffe E, Pinho V, Souza DG, Silva AF, Russo RC, Guabiraba R, Pereira CA, Carvalho FM, Barsante MM, Correa-Oliveira R et al: Potential role of the chemokine macrophage inflammatory protein 1α in human and experimental schistosomiasis. Infect Immun (2005)73(4):2515-2523.
98. Machado FS, Koyama NS, Carregaro V, Ferreira BR, Milanezi CM, Teixeira MM, Rossi MA, Silva JS: CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi. J Infect Dis (2005)191(4):627-636.
99. Marino AP, da Silva A, dos Santos P, Pinto LM, Gazzinelli RT, Teixeira MM, Lannes-Vieira J: Regulated on activation, normal T cell expressed and secreted (RANTES) antagonist (met-RANTES) controls the early phase of Trypanosoma cruzi-elicited myocarditis. Circulation (2004)110(11):1443-1449.
100. Roffe E, Oliveira F, Souza AL, Pinho V, Souza DG, Souza PR, Russo RC, Santiago HC, Romanha AJ, Tanowitz HB, Valenzuela JG et al: Role of CCL3/MIP-1α and CCL5/RANTES during acute Trypanosoma cruzi infection in rats. Microbes Infect (2010): doi:10.1016/j.micinf.2010.04.011.
101. Talvani A, Rocha MO, Ribeiro AL, Correa-Oliveira R, Teixeira MM: Chemokine receptor expression on the surface of peripheral blood mononuclear cells in chagas disease. J Infect Dis (2004)189(2):214-220.
102. Winter C, Herbold W, Maus R, Langer F, Briles DE, Paton JC, Welte T, Maus UA: Important role for CC chemokine ligand 2-dependent lung mononuclear phagocyte recruitment to inhibit sepsis in mice infected with Streptococcus pneumoniae. J Immunol (2009)182(8):4931-4937.
103. Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G, Cervellera MN, Di Cioccio V, Cesta MC, Galliera E, Martinez FO et al: Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury. Proc Natl Acad Sci USA (2004)101(32):11791-11796. • Describes a novel allosteric non-competitive CXCR1/CXCR2 antagonist, reparixin, that prevents receptor signaling.
104. Cugini D, Azzollini N, Gagliardini E, Cassis P, Bertini R, Colotta F, Noris M, Remuzzi G, Benigni A: Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int (2005)67(5):1753-1761.
105. Garau A, Bertini R, Colotta F, Casilli F, Bigini P, Cagnotto A, Mennini T, Ghezzi P, Villa P: Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia. Cytokine (2005)30(3):125-131.
106. Souza DG, Bertini R, Vieira AT, Cunha FQ, Poole S, Allegretti M, Colotta F, Teixeira MM: Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br J Pharmacol (2004)143(1):132-142.
107. Abjenix Inc: Abgenix releases results of a phase 2a study with ABX-IL8 in rheumatoid arthritis. Press Release (2002): January 03.
108. Barsante MM, Cunha TM, Allegretti M, Cattani F, Policani F, Bizzarri C, Tafuri WL, Poole S, Cunha FQ, Bertini R, Teixeira MM: Blockade of the chemokine receptor CXCR2 ameliorates adjuvant-induced arthritis in rats. Br J Pharmacol (2008)153(5):992-1002.
109. Coelho FM, Pinho V, Amaral FA, Sachs D, Costa VV, Rodrigues DH, Vieira AT, Silva TA, Souza DG, Bertini R, Teixeira AL et al: The chemokine receptors CXCR1/CXCR2 modulate antigeninduced arthritis by regulating adhesion of neutrophils to the synovial microvasculature. Arthritis Rheum (2008)58(8):2329-2337.
110. Cunha TM, Barsante MM, Guerrero AT, Verri WA Jr, Ferreira SH, Coelho FM, Bertini R, Di Giacinto C, Allegretti M, Cunha FQ, Teixeira MM: Treatment with DF 2162, a non-competitive allosteric inhibitor of CXCR1/2, diminishes neutrophil influx and inflammatory hypernociception in mice. Br J Pharmacol (2008)154(2):460-470.
111. Cardona AE, Sasse ME, Liu L, Cardona SM, Mizutani M, Savarin C, Hu T, Ransohoff RM: Scavenging roles of chemokine receptors: Chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues. Blood (2008)112(2):256-263. •• Provides data indicating that chemokine receptors are important negative modulators or scavengers of their own ligands, providing an important homeostatic mechanism to limit excessive chemokine levels.
112. Weber C, Koenen RR: Fine-tuning leukocyte responses: Towards a chemokine 'interactome'. Trends Immunol (2006)27(6):268-273.
113. Pease JE, Horuk R: Chemokine receptor antagonists: Part 1. Expert Opin Ther Pat (2009)19(1):39-58.
114. Pease JE, Horuk R: Chemokine receptor antagonists: Part 2. Expert Opin Ther Pat (2009)19(2):199-221.